Quotables
"The idea that cavalry will be replaced by these iron coaches is absurd. It is little short of treasonous."
Aide-de-camp to Field Marshal Haig ; At a tank demonstration, 1916
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 6087555 | Mice lacking expression of osteoprotegerin Disclosed is a mouse in which expression of the gene encoding Osteoprotegerin is suppressed. Also disclosed is a nucleic acid construct useful in preparing such a mouse, and a cell line containing such construct.... | 07/11/2000 |
| 6080911 | Mice models of growth hormone insensitivity The present invention provides mouse models of growth hormone insensitivity including Laron syndrome. In particular, the present invention provides transgenic mice incapable of expressing functional growth hormone receptor including mice which further can... | 06/27/2000 |
| 6069010 | High throughput gene inactivation with large scale gene targeting The present invention provides a vector system that is useful for the generation of mutations in a recombination-based construction method. The invention further includes the incorporation of mutations generated by the method of the present invention into... | 05/30/2000 |
| 6066778 | Transgenic mice expressing APC resistant factor V The present invention relates to compositions and methods for the screening of compounds for anticoagulant activity. In particular, the present invention relates to non-human transgenic animals expressing activated protein C ("APC")-resistant factor V pro... | 05/23/2000 |
| 6057489 | MmRad51-deficient cells and transgenic mice The present invention discloses MmRad51-deficient transgenic mice and mouse cells, as well as MmRad51/p53-deficient transgenic mice and mouse cells. Also described is a method of screening for proteins that rescue the senescence phenotype in MmRad51/p53-d... | 05/02/2000 |
| 6030794 | Genetically engineered mice and cell lines containing alterations in the genes encoding retinoic acid receptor and retinoid X receptor proteins The present invention provides mice which are deficient in the normal expression of one or more members of the RAR or RXR class of receptors, mice which are heterozygous for such deficiency, and to cell lines, preferably pluripotent or totipotent cell lin... | 02/29/2000 |
| 6013858 | Mouse lacking heart-muscle adenine nucleotide translocator protein and methods Provided are transgenic mice genetically engineered for a deficiency of the heart-skeletal muscle isoform of the adenine nucleotide translocator protein (Ant1). These mice exhibit histological, biochemical and physiological signs of deficiency in oxidativ... | 01/11/2000 |
| 6008434 | Growth differentiation factor-11 transgenic mice A transgenic mouse whose genome comprises a disruption of the endogenous growth differentiation factor-11 (GDF-11) gene is disclosed. Also disclosed are methods for making such mice. The mice exhibit a phenotype of increased muscle tissue.... | 12/28/1999 |
| 6002066 | H2-M modified transgenic mice A transgenic mouse with alterations in the H2-Ma gene is prepared by introduction of an altered H2-Ma gene into a host mouse. The resulting transgenic mice do not produce functional H2-M molecules.... | 12/14/1999 |
| 5994618 | Growth differentiation factor-8 transgenic mice A transgenic mouse whose genome comprises a disruption of the endogenous growth differentiation factor-8 (GDF-8) gene is disclosed. Also disclosed are methods for making such mice. The transgenic mice exhibit a phenotype of increased muscle tissue.... | 11/30/1999 |
| 5981830 | Knockout mice and their progeny with a disrupted hepsin gene The present invention provides a transgenic mouse comprising a disrupted hepsin gene. In particular, the invention provides methods of making the transgenic mouse comprising the disrupted hepsin gene by utilizing a hepsin targeting vector for homologous r... | 11/09/1999 |
| 5981829 | ƊNur77 transgenic mouse The present invention provides a transgenic mouse containing a transgene, said transgene comprising a truncated Nur77 (ƊNur77) gene. Also provided is a double transgenic mouse, wherein said double transgenic mouse comprises the ƊNur77 transgenic mouse b... | 11/09/1999 |
| 5955645 | Thrombin receptor deficient transgenic mice A transgenic animal with alterations in an thrombin receptor gene is prepared by introduction of an altered thrombin receptor gene into a host animal. The resulting transgenic animals do not produce functional thrombin receptor molecules.... | 09/21/1999 |
| 5922927 | Methods for producing tetracycline-regulated transgenic mice Transgenic mice carrying two transgenes, the first coding for a transactivator fusion protein comprising a tet repressor and a polypeptide which directly or indirectly activates in eucaryotic cells, and the second comprising a gene operably linked to a mi... | 07/13/1999 |
| 5919997 | Transgenic mice having modified cell-cycle regulation The present invention relates to transgenic mice in which the biological function of at least one cell cycle regulatory proteins of the INK4 family is altered.... | 07/06/1999 |
| 5907080 | Method for development of transgenic dwarf goats The invention features a method which includes the following steps: (a) introducing a transgene into a zygote of a dwarf goat, (b) transplanting the zygote into a pseudopregnant non-dwarf goat, and (c) allowing the zygote to develop to term. In another as... | 05/25/1999 |
| 5907079 | MSH2 disrupted mice develop lymphomas Non-human mammals comprising a disrupted MSH2 gene are disclosed. More particularly, animals having a disruption in one or both alleles of the MSH2 gene or a homolog of the MSH2 gene are disclosed. Animals homozygous for the disruption are viable past the... | 05/25/1999 |
| 5898094 | Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes A method of preparing a transgenic animal model with enhanced, accelerated pathology for Alzheimer's Disease (AD) and the transgenic animal made by the method is disclosed. The method includes producing an F1 generation by crossing a first and ... | 04/27/1999 |
| 5869718 | Homologous recombination for animal model exhibiting reduced levels or elimination of a neuronal intermediate filament protein Transgenic non-human mammals and methods of preparing such mammals are disclosed. Homologous recombination is employed to inactivate genes, particularly genes coding for neuronal intermediate filaments. These animals, whose phenotype is characterized by r... | 02/09/1999 |
| 5859307 | Mutant RAG-1 deficient animals having no mature B and T lymphocytes Immunodeficient animals are generated by introducing a mutation in RAG-1 into the germline of the animals via gene targeting in embryonic stem cells. The production of mutant RAG-1 deficient mice is detailed. RAG-1 deficient mice have no mature B and T ly... | 01/12/1999 |
| 5859310 | Mice transgenic for a tetracycline-controlled transcriptional activator Transgenic mice carrying two transgenes, the first coding for a transactivator fusion protein comprising a tet repressor and a polypeptide which directly or indirectly activates transcription of a tet operator-linked gene in eucaryotic cells, and the seco... | 01/12/1999 |
| 5850004 | Transgenic mouse deficient in inducible nitric oxide synthase The present invention provides an inducible nitric oxide synthase ("iNOS")-deficient transgenic mouse, novel replacement vectors designed for the disruption of the iNOS gene, embryonic stem (ES) cells which are singly allelic relative to the deficient iNO... | 12/15/1998 |
| 5849991 | Mice homozygous for an inactivated 1,3-galactosyl transferase gene Human pre-formed xenoantibodies play an important role in the hyperacute rejection response in human xenotransplantation. Disclosed are materials and methods for removing or neutralizing such antibodies. Also disclosed are materials and methods for reduci... | 12/15/1998 |
| 5824840 | Diabetes-inducing transgenic mouse Disclosed in this invention is a transgenic mouse containing rcombinant DNA including a promoter and a heat shock protein 70 gene attached to downstream of the promoter. Transgenic mice line inducing non-insulin dependent diabetes having a blood glucose l... | 10/20/1998 |
| 5817912 | Transgenic mice with disrupted NPY Y1 receptor genes The present invention is directed to transgenic animals which have been engineered by homologous recombination to be deficient in the expression of the neuropeptide Y Y1 receptor. The invention encompasses the DNA constructs and engineered embryonic stem ... | 10/06/1998 |
| 5777195 | Knockout mutant mouse for DARPP-32 and use thereof A knockout mouse containing a non-functional allele for the gene that naturally encodes and expresses functional DARPP-32 is disclosed. This mouse contains two non-functional alleles for the gene that naturally encodes and expresses functional DARPP-32, a... | 07/07/1998 |
| 5675063 | Immortalized rabbit hybridoma fusion partner Novel methods are provided for producing rabbit fusion partners for the production of specific binding proteins, particularly immunoglobulins. Nuclei of rabbit fertilized ova are microinjected with an oncogene to express specifically in lymphoid cells (i.... | 10/07/1997 |
| 5602306 | Synthesis of functional human hemoglobin and other proteins in erythroid tissues of transgenic animals The present invention relates to the synthesis of functional human hemoglobin and other proteins in erythroid tissues of transgenic non-human animals and erythroid cell lines. It is based on the discovery that two of the five hypersensitivity sites of the... | 02/11/1997 |
| 5574205 | Homologous recombination for universal donor cells and chimeric mammalian hosts Homologous recombination is employed to inactivate genes, particularly genes associated with MHC antigens. Particularly, each of the 댢- microglobulin gene and the IFN-γR gene is inactivated for reducing or eliminating the expression of ... | 11/12/1996 |
| 5416260 | Homologous recombination for universal donor cells and chimeric mammalian hosts Homologous recombination is employed to inactivate genes, particularly genes associated with MHC antigens. Particularly, the 댢 -microglobulin gene is inactivated for reducing or eliminating Class I MHC antigens. The resulting cells may b... | 05/16/1995 |
| 5221778 | Multiplex gene regulation A transgenic mouse offspring produced by the mating of a first transgenic mouse carrying a transresponder transgene whose expression is regulated by a viral gene product of HSV-1 and a second transgenic mouse carrying a transactivator transgene. A process... | 06/22/1993 |
